More Axil Capital's Recent News
Axil Capital Launches its Second Life Science Fund (ALHF II)
Axil Capital Advisors K.K. announces the appointment of Mr. Yasuto Hamanishi, former Deputy President & Executive Officer Mizuho Securities Co Ltd, as its Executive Advisor as of November 1, 2022.
Cranebio added to our portfolio companies.
Angiocrine Bioscience added to our portfolio companies.
We moved to our new office in Minato-ku, Nishi-shimbashi.
Our portfolio company, Perseus Proteomics (4882), successfully completed its IPO listing on the Tokyo Stock Exchange Mothers Board.
Our portfolio company, C4 Therapeutics (CCCC), successfully completed its IPO listing on the NASDAQ exchange.
Our portfolio company, Frequency Therapeutics (FREQ), successfully completed its IPO listing on the NASDAQ exchange.
More Portfolio Companies' Recent News
Perseus Proteomics presented an interim report on the PPMX-T003 Phase I study at the 65th American Society of Hematology (ASH) Annual Meeting.
GEXVal executed a third-party allotment of new shares.
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology.
The results of the joint research between Cranebio and Unicharm were distributed as a press release.
Cellusion was selected for the "Capital Investment Support Program for Breakthrough Business Promotion".
Cranebio has raised a total of 250 million yen through a Series A round.
United Immunity announced completion of fundraising and grant approval.
Techsomed announces FDA Clearance for Ablation Treatment Planning and Confirmation Software.
Jolly Good and Otsuka Pharmaceutical Launch New VR Employment Support Services! The SST-VR program "FACEDUO" is now expanding to vocational support centers and sheltered workshops.
Suono Bio has received an exclusive patent option from the Massachusetts Institute of Technology (MIT) for RoboCap.
Cellusion received MEXT Minister’s Award under the Award for Academic Startups 2023.
Japan's Minister of Health, Labor and Welfare experienced the employment support VR of Jolly Good.
Perseus Proteomics presented an interim report of the PPMX-T003 clinical trial at The 13th JSH International Symposium 2023
Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform.
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Appli-cation for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer.
Techsomed Announces Field Evaluation of its image guided ablation therapy software using GE HealthCare LOGIQ™ ultrasound systems at top US clinical sites.
Dr. Taku Kambayashi, founder of Abrax Japan, appeared on NTV's "Learning with Kazu-Laser.
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients.
Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round.
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial.
Luca Science gave a lecture at the Japan Society of Obstetrics and Gynecology (JSOG) and the presenter, Dr. Yosuke Matsumiya, received the JSOG Congress Award.
Perseus Proteomics reported that a Phase I study of PPMX-T003 confirmed the safety and efficacy of the drug in the first three patients treated with the drug.
Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients.
Himuka AM Pharma has completed a Phase I clinical trial of HM201 in Australia.
Cranebio presented at a conference on the development of rapid water quality testing in collaboration with Metawater, Co., Ltd.
Perseus Proteomics Completes PMDA Investigation of Aggressive NK Cell Leukemia Clinical Trial Plan Notification.
Ricoh Biomedical Startup Fund has decided to invest in United Immunity.
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC.
Jolly Good jointly developed medical VR with Harvard University Hospital to enter the U.S. market.
United Immunity has published an academic paper on UI-201.
LUCA Science was selected as one of the 2023 Deep Tech Top 10 by Forbes Japan magazine.
Suono Bio announces Formulation-Agnostic Platform for the delivery of RNA therapeutics.
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors.
An article on Perseus' Phase I study of PPMX-T003 in healthy subjects was published online in Clinical Pharmacology in Drug Development.
Suono Bio announces first patient dosed with its SuonoCalm™ Platform.
TechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS.
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial.
LUCA Science presented its research findings at the Annual Meeting of the American Society of Hematology.
Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology.
JollyGood has initiated a specific clinical study of digital therapeutic VR for depression with Teijin Pharma.
Cranebio presented its latest research results on ovulation date prediction at an academic conference in collaboration with Unicharm Corporation.
TechsoMed Completes Enrollment in United States Pivotal Trial of BioTraceIO Software for Liver Ablation Outcomes Assessment.
TechsoMed Announces Completion of Full Enrollment in Pivotal U.S trial Evaluating its BioTraceIO Software for Liver Ablation Outcomes Assessment in Liver Cancer Patients.
Jolly Good has launched FACEDUO, a VR support program for schizophrenia, with Otsuka Pharmaceutical.
Allgenesis selected as one of the 3 finalists for the Eyecelerator pitch at the American Academy of Ophthalmology conference on September 29, 2022
The educational effects of the medical education VR developed by Jolly Good and Hiroshima University were published as an article in the American Journal of Infection Control, an American medical journal.
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
TOP 11 of TAcc+ International Program 2022.
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors.
AACR: C4's multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve.
Allgenesis announces first patient dosed in the U.S. for the Phase 1b trial evaluating AG-80308 for the treatment of dry eye disease.
Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema.
LUCA Science was featured in an article in BIOCENTURY.
LUCA Science and Kyowa Kirin announce joint research agreement on mitochondrial disease treatment with novel mitochondria modality.
Research on mice that ‘sweat out’ fat wins STAT Madness for University of Pennsylvania.
Angiocrine Bioscience announces first patient dosed in pivotal phase 3 clinical trial of AB-205 and completion of Series B financing.
LUCA Science raised 3.86 billion yen in Series B.
United Immunity completed Series B round.
United Immunity has entered into a joint research agreement with Xyphos/Astellas on cancer immunotherapy program.
United Immunity completed Series A2 round.
AIBIOS is working on three active programs to resolve unmet medical needs.
© Axil Capital All Rights Reserved
